Zimmer Biomet Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Zimmer Biomet Holdings, Inc. on October 7, 2025. The report details the completion of a previously announced acquisition.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels for Zimmer Biomet Holdings, Inc. The document focuses exclusively on the terms of a specific corporate transaction.
Material Changes
The primary material event reported is the closing of the merger with Monogram Technologies Inc. ("Monogram").
- Transaction Status: The merger closed on October 7, 2025. Monogram is now a wholly-owned subsidiary of Zimmer Biomet.
- Consideration for Monogram Common Stock: Shareholders received $4.04 in cash per share plus one contractual contingent value right (CVR).
- Consideration for Preferred Stock: Series D holders received $2.25 in cash plus accrued dividends; Series E holders received $100.00 in cash per share.
- Exclusions: Shares owned by the Company or its subsidiaries were canceled, and shares subject to valid appraisal rights were excluded from the conversion.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or a discussion of general risks. The transaction involves a Contingent Value Rights Agreement, which represents a potential future liability dependent on specific conditions not detailed in this summary text.
Investor Verification Checklist
- Verify the terms and potential payout conditions of the Contingent Value Rights (CVRs) issued to Monogram common shareholders.
- Review the press release (Exhibit 99.1) for strategic rationale and integration plans.
- Confirm the impact of the acquisition on Zimmer Biomet's consolidated balance sheet and debt covenants in subsequent quarterly filings.
- Check for any regulatory approvals or conditions precedent that were satisfied to allow the closing.